全文获取类型
收费全文 | 251篇 |
免费 | 28篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 26篇 |
口腔科学 | 3篇 |
临床医学 | 30篇 |
内科学 | 119篇 |
皮肤病学 | 3篇 |
神经病学 | 1篇 |
特种医学 | 6篇 |
外科学 | 25篇 |
综合类 | 14篇 |
预防医学 | 20篇 |
眼科学 | 6篇 |
药学 | 16篇 |
肿瘤学 | 5篇 |
出版年
2024年 | 2篇 |
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 5篇 |
2019年 | 2篇 |
2018年 | 11篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 6篇 |
2013年 | 7篇 |
2012年 | 18篇 |
2011年 | 14篇 |
2010年 | 4篇 |
2009年 | 4篇 |
2008年 | 8篇 |
2007年 | 12篇 |
2006年 | 6篇 |
2005年 | 8篇 |
2004年 | 13篇 |
2003年 | 7篇 |
2002年 | 6篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 16篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1993年 | 4篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1971年 | 2篇 |
1963年 | 1篇 |
1932年 | 2篇 |
1881年 | 1篇 |
排序方式: 共有279条查询结果,搜索用时 15 毫秒
1.
Lidong Zhang James E Littlejohn Yu Cui Xiaobo Cao Chander Peddaboina W Roy Smythe 《Molecular cancer》2010,9(1):110
Background
Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy. 相似文献2.
Jimin Lee Meghan Anne Littlejohn Zachary Simmons 《International journal of speech-language pathology》2017,19(2):195-204
Purpose: The purpose is to investigate acoustic and tongue body kinematic vowel dispersion patterns and vowel space in speakers with and without dysarthria secondary to amyotrophic lateral sclerosis (ALS).Method: Acoustic and tongue kinematic vowel spaces were examined at the same time sampling point using electromagnetic articulography in 11 speakers with dysarthria secondary to ALS and 11 speakers without dysarthria. Tongue kinematic data were collected from the tongue body sensor (~25?mm posterior from the tongue apex). A number of acoustic and tongue body kinematic variables were tested.Result: The result showed that the acoustic and tongue kinematic vowel dispersion patterns are different between the groups. Acoustic and tongue body kinematic vowel spaces are highly correlated; however, unlike acoustic vowel space, tongue body kinematic vowel space was not significantly different between the groups.Conclusion: Both acoustic and tongue kinematic vowel dispersion patterns are sensitive to the group difference, especially with high vowels. The tongue kinematic vowel space approach is too crude to differentiate the speakers with dysarthria secondary to ALS from speakers without dysarthria. To examine tongue range of motion in speakers with dysarthria, a more refined articulatory kinematic approach needs to be examined in the future. 相似文献
3.
Tymms Kathleen Butcher Belinda E. Sletten Tracey L. Smith Tegan O’Sullivan Catherine Littlejohn Geoffrey Sadler Ricky Tronnberg Rebecca Griffiths Hedley 《Clinical rheumatology》2022,41(4):1105-1114
Clinical Rheumatology - Sleep disturbance and fatigue are commonly reported in ankylosing spondylitis (AS) but specific prevalence and the relationship to disease control are unknown. This... 相似文献
4.
Summary Three cases of generalized calcium pyrophosphate dihydrate deposition disease and roentgenographic sacroiliac abnormalities (chondrocalcinosis, inflammatory change and degenerative change) are described. 相似文献
5.
MacDonald TM Reginster JY Littlejohn TW Richard D Lheritier K Krammer G Rebuli R 《Journal of hypertension》2008,26(8):1695-1702
OBJECTIVES: Nonsteroidal anti-inflammatory drugs vary in their impact on blood pressure and the effect of lumiracoxib 100 mg once daily has not been studied previously. To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries. METHODS: Hypertensive osteoarthritis patients of 50 years at least whose office blood pressure was less than 140/90 mmHg on stable antihypertensive treatment were randomized to lumiracoxib (n = 394) 100 mg once daily or ibuprofen 600 mg three times daily (n = 393) and 24-h ambulatory blood pressure monitoring was performed at baseline and end of study. The primary outcome measure was a comparison of the change in 24-h mean systolic ambulatory blood pressure from baseline to week 4. Secondary analyses included other blood pressure-related endpoints and efficacy (pain) measurements. RESULTS: Compared with baseline, the 24-h mean systolic ambulatory blood pressure (least square mean) decreased in lumiracoxib-treated patients (-2.7 mmHg) and increased in ibuprofen-treated patients (+2.2 mmHg) at 4 weeks, estimated difference -5.0 mmHg (95% confidence interval -6.1 to -3.8) in favour of lumiracoxib. The 24-h mean diastolic ambulatory blood pressure changes were -1.5 mmHg (lumiracoxib), +0.5 mmHg (ibuprofen), difference -2.0 mmHg (95% confidence interval -2.7 to -1.3). Efficacy results were comparable. CONCLUSIONS: Treatment with lumiracoxib 100 mg once daily resulted in clinically significant lower blood pressure compared with ibuprofen 600 mg three times daily in osteoarthritis patients with well controlled hypertension. 相似文献
6.
7.
Lauren Desrosiers Sarah Scollon Rebecca Littlejohn Kimberly Nugent Rebecca Althaus Jessica Corredor Emily Berenson Rachel Wyatt Timothy Griffin Kelly Vallance Jonathan Gill Gail Tomlinson Juan Carlos Bernini Angshumoy Roy George Miles Jacquelyn Reuther Shashikant Kulkarni Christine Eng Sharon Plon 《Molecular genetics and metabolism》2021
8.
Switching leukemia cell phenotype between life and death 总被引:4,自引:0,他引:4
9.
10.
Kereiakes DJ Chrysant SG Izzo JL Littlejohn T Oparil S Melino M Lee J Fernandez V Heyrman R 《Journal of clinical hypertension (Greenwich, Conn.)》2012,14(3):149-157
J Clin Hypertens (Greenwich). 2012;14:149–157. ©2012 Wiley Periodicals, Inc. Most patients with hypertension require combination therapy in order to achieve blood pressure (BP) goals. This 40‐week open‐label extension of the 12‐week double‐blind Tri ple Therapy With Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hyperten si ve Patient s Study (TRINITY) evaluated the efficacy and safety of triple‐combination treatments with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide (OM/AML/HCTZ) in 2112 participants with moderate to severe hypertension. Following 2 weeks of initial treatment with OM 40/AML 5/HCTZ 12.5 mg, participants not achieving BP goal were titrated to OM 40/AML 5/HCTZ 25 mg or OM 40/AML 10/HCTZ 12.5 mg on a randomized basis. At week 16, participants who did not achieve BP goal were further titrated to OM 40/AML 10/HCTZ 25 mg. At the end of the study, 44.5% to 79.8% of participants reached BP goal and the mean BP decreased from 168.6/100.7 mm Hg (baseline BP at randomization) to 125.0 to 136.8 mm Hg/77.8 to 82.5 mm Hg, depending on treatment. Long‐term treatment with OM/AML/HCTZ was well tolerated and effective with no new safety concerns. 相似文献